Fox Run Management L.L.C. Takes $92,000 Position in Stoke Therapeutics, Inc. $STOK

Key Points

• Fox Run Management L.L.C. acquired 13,780 shares of Stoke Therapeutics, valued at approximately $92,000, indicating continued institutional interest in the company.
• Stoke Therapeutics reported an EPS of ($0.40), surpassing estimates, but its revenue of $13.82 million fell short of analyst expectations of $31.51 million.
• Chardan Capital and other analysts have reaffirmed positive ratings with price targets ranging from $22.00 to $30.00, reflecting a strong overall sentiment towards the stock.

Fox Run Management L.L.C. bought a new position in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 13,780 shares of the company's stock, valued at approximately $92,000.

Other institutional investors have also recently made changes to their positions in the company. GAMMA Investing LLC grew its position in shares of Stoke Therapeutics by 1,842.0% during the first quarter. GAMMA Investing LLC now owns 5,360 shares of the company's stock worth $36,000 after purchasing an additional 5,084 shares in the last quarter. US Bancorp DE grew its position in shares of Stoke Therapeutics by 9,743.9% during the first quarter. US Bancorp DE now owns 11,222 shares of the company's stock worth $75,000 after purchasing an additional 11,108 shares in the last quarter. Tower Research Capital LLC TRC grew its position in shares of Stoke Therapeutics by 70.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 11,930 shares of the company's stock worth $132,000 after purchasing an additional 4,918 shares in the last quarter. Invesco Ltd. purchased a new stake in shares of Stoke Therapeutics during the fourth quarter worth about $133,000. Finally, ProShare Advisors LLC purchased a new position in Stoke Therapeutics during the 4th quarter valued at approximately $139,000.

Stoke Therapeutics Trading Down 0.4%

Shares of STOK stock traded down $0.07 on Wednesday, reaching $19.30. 596,777 shares of the company's stock were exchanged, compared to its average volume of 916,439. Stoke Therapeutics, Inc. has a 52 week low of $5.35 and a 52 week high of $19.97. The stock has a market capitalization of $1.06 billion, a PE ratio of 22.71 and a beta of 1.15. The company's fifty day simple moving average is $13.77 and its 200 day simple moving average is $10.57.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.57) by $0.17. Stoke Therapeutics had a return on equity of 18.32% and a net margin of 26.25%.The firm had revenue of $13.82 million during the quarter, compared to analyst estimates of $31.51 million. As a group, sell-side analysts predict that Stoke Therapeutics, Inc. will post -2.01 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on STOK shares. Needham & Company LLC restated a "buy" rating and set a $22.00 price target on shares of Stoke Therapeutics in a report on Tuesday, July 1st. HC Wainwright cut their price target on Stoke Therapeutics from $47.00 to $35.00 and set a "buy" rating for the company in a report on Wednesday, May 14th. Cantor Fitzgerald upgraded Stoke Therapeutics to a "strong-buy" rating in a report on Wednesday, May 14th. Wedbush raised their price objective on Stoke Therapeutics from $16.00 to $22.00 and gave the company an "outperform" rating in a research note on Wednesday, August 13th. Finally, Chardan Capital reaffirmed a "buy" rating and issued a $24.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday, August 13th. Two research analysts have rated the stock with a Strong Buy rating and seven have assigned a Buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $25.57.

Insiders Place Their Bets

In other Stoke Therapeutics news, General Counsel Jonathan Allan sold 13,712 shares of Stoke Therapeutics stock in a transaction on Wednesday, August 13th. The stock was sold at an average price of $15.00, for a total transaction of $205,680.00. Following the completion of the sale, the general counsel directly owned 19,631 shares of the company's stock, valued at $294,465. The trade was a 41.12% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Barry Ticho sold 4,504 shares of Stoke Therapeutics stock in a transaction on Friday, August 1st. The shares were sold at an average price of $12.82, for a total value of $57,741.28. Following the sale, the insider directly owned 16,775 shares of the company's stock, valued at approximately $215,055.50. This trade represents a 21.17% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 26,432 shares of company stock valued at $345,775. 9.50% of the stock is currently owned by corporate insiders.

Stoke Therapeutics Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.